Indivior (NASDAQ:INDV) Downgraded by Zacks Research to “Hold”

Indivior (NASDAQ:INDV) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

INDV has been the subject of a number of other research reports. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd. Craig Hallum reaffirmed a “buy” rating and issued a $41.00 price objective on shares of Indivior in a research report on Friday, October 31st. Piper Sandler reiterated an “overweight” rating and set a $41.00 price objective (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. HC Wainwright upped their target price on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday. Finally, Northland Securities set a $40.00 price target on shares of Indivior in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.57.

Indivior Stock Down 1.1%

Indivior stock opened at $33.63 on Tuesday. The firm has a fifty day moving average of $34.30 and a 200-day moving average of $26.39. Indivior has a 52-week low of $7.62 and a 52-week high of $38.00. The firm has a market capitalization of $4.20 billion, a P/E ratio of 36.55 and a beta of 0.75.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The firm had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. On average, research analysts expect that Indivior will post 1.22 EPS for the current fiscal year.

Insider Transactions at Indivior

In related news, Director Barbara Ryan bought 775 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 1,963 shares in the company, valued at $69,470.57. This trade represents a 65.24% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel A. Ninivaggi purchased 775 shares of Indivior stock in a transaction dated Monday, January 5th. The shares were bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director directly owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. The trade was a 4.80% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 4,871 shares of company stock valued at $172,385 over the last ninety days.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently bought and sold shares of INDV. Oaktree Capital Management LP increased its holdings in shares of Indivior by 2,241.6% in the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after acquiring an additional 246,776,273 shares during the last quarter. Two Seas Capital LP lifted its stake in Indivior by 0.4% during the second quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock worth $168,151,000 after purchasing an additional 41,018 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Rubric Capital Management LP increased its stake in Indivior by 31.6% during the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock valued at $68,499,000 after purchasing an additional 1,117,140 shares during the last quarter. Finally, Newtyn Management LLC raised its holdings in shares of Indivior by 61.1% during the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after purchasing an additional 1,592,982 shares during the period. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.